NSRX
NASUS PHARMA LTDData as of 2026 Q2 (06-30) · 13F snapshot
Summary
NASUS PHARMA LTD (NSRX) is held as common stock by 2 tracked hedge-fund managers, with a combined reported value of ~$119.7K; the largest are Ken Griffin, Renaissance Technologies. This quarter: 2 new. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · LowThis quarter · Heating up
Common-stock holders2
Congress trades0
Price$3.57vs quarter-end+2.00%
Sectors0
This quarter's moves
Top holderNew2
Added0
Trimmed / sold0
Ken GriffinCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.